GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday ...

The football legend, 44, has revealed another huge milestone for his family, announcing that his youngest son has taken part ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and currently trading at $756.99.The company has been around since 1876 and ...

Eli Lilly said it received Food and Drug Administration ... The treatment, developed by the pharmaceutical company under the brand name Omvoh, is now approved to treat two types of inflammatory ...

The company only reported Q3 revenues of $11.44 billion, and the guidance for Q4 was a very aggressive revenue target of $13.9 billion. Eli Lilly only reached revenues of $13.5 billion ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In one of his latest appearances on CNBC's Squawk on the Street, Jim Cramer ...

Eli Lilly forecasts $45 billion in 2024 revenue ... Get the Real Story Behind Every Major Earnings Report The company's expected 2024 revenue is $400 million, or about 3%, below the guidance ...

Eli Lilly announced preliminary fourth-quarter revenue of roughly $13.5 billion, or $400 million below the low end of its guidance, driven by slower-than-expected US market growth and lower ...

Shares in Meta fell more than 2% on Tuesday, following reports that the social media company is planning to cut around 5% of its workforce through performance-based terminations. According to a ...

Eli Lilly shares climbed 32% last year but have slumped more than 16% since October after the company reported third quarter sales of the two drugs below Wall Street’s expectations, prompting ...